Printer Friendly

UNIMED REPORTS REVENUE GROWTH OF 46 PERCENT IN FISCAL FIRST QUARTER

 UNIMED REPORTS REVENUE GROWTH OF 46 PERCENT IN FISCAL FIRST QUARTER
 SOMERVILLE, N.J., Feb. 11 /PRNewswire/ -- UNIMED, Inc. (NASDAQ: UMED) reported total consolidated revenues for the first quarter of fiscal 1992 ended Dec. 31, of $1,764,000, $559,000 or 46 percent greater than consolidated revenues of $1,205,000 for the first quarter of fiscal 1991. The company's net loss was $443,000 or 10 cents per share for the fiscal 1992 quarter as compared to a net loss of $278,000 or 9 cents per share for the fiscal 1991 quarter.
 "During the first quarter of fiscal 1992, we made continued progress in the development and distribution of Marinol(R)(dronabinol), identified a new product, UNIMIST(TM) Mouth Moistener, for introduction by the UNIMED sales force in February and announced several significant developments with the Medisperse Technology," said Harold J. Tenoso, Ph.D., UNIMED's chairman and chief executive officer.
 Pharmaceutical segment revenues increased $433,000 or 71 percent in the fiscal 1992 quarter to $1,040,000. Marinol sales increased $233,000 or 70 percent to $564,000 while Serc(R) betahistine HCI) sales increased $57,000 or 26 percent to $275,000. Research contract revenues increased $142,000 or 245 percent to $200,000. Chemical segment revenues increased $119,000 or 21 percent in the fiscal 1992 quarter to $686,000.
 Sales and marketing expenses increased $370,000 to $494,000 primarily due to the costs of the UNIMED sales force that was initiated in fiscal 1991. Research and development expenses increased $252,000 to $720,000 primarily due to the expansion of the Marinol development program for appetite stimulation and prevention of weight loss in AIDS patients.
 UNIMED, Inc. specializes in the development and marketing of pharmaceuticals, with emphasis on cancer therapy and supportive care of cancer patients and AIDS patients.
 UNIMED Inc. and Subsidiaries
 First Quarter Ended Dec. 31 1991 1990
 Total revenues $1,764,000 $1,205,000
 Net loss (443,000) (278,000)
 Net loss per share $(.10) $(.09)
 -0- 2/11/92
 /CONTACT: Charles P. Harrison, president of UNIMED, 908-526-6894/
 (UMED) CO: UNIMED, Inc. ST: New Jersey IN: MTC SU: ERN


PS -- NY005 -- 8663 02/11/92 09:04 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 11, 1992
Words:370
Previous Article:LEWIS GALOOB TOYS ANNOUNCES OFFICER APPOINTMENTS
Next Article:BACHMAN TO MARKET NEW SOFTWARE TOOL FROM RAPID SYSTEM DEVELOPMENT
Topics:


Related Articles
UNIMED REPORTS RECORD SALES OF MARINOL IN FISCAL YEAR RESULTS
UNIMED REPORTS SECOND QUARTER RESULTS
UNIMED REPORTS HIGHER SALES, EARNINGS COMPARED WITH LOSS FOR FIRST QUARTER
UNIMED PHARMACEUTICALS REPORTS HIGHER REVENUES AND EARNINGS IN FIRST QUARTER
Unimed Pharmaceuticals Reports Higher Revenues And Earnings For Second Quarter, Six Months
Unimed Pharmaceuticals Reports Higher Revenues and Earnings for Third Quarter and First Nine Months
Unimed Reports 1996 Results: Earnings Exceed Published Estimates
Unimed Pharmaceuticals Reports Higher Revenues in First Quarter
Unimed Reports 1996 Results: Earnings Exceed Published Estimates
Unimed Announces 96% Revenue Growth for First Half of 1998

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters